IMS 2186 |
| Catalog No.GC47454 |
An anti-choroidal neovascularization agent
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1031206-36-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IMS 2186 is an anti-choroidal neovascularization agent.1 It inhibits proliferation of NIH3T3 mouse and IMR-90 human fibroblasts (IC50s = 0.5-3 µM), as well as in a panel of eight human cancer cell lines, including ovarian, lung, colon, and pancreatic cancer cells (IC50s = 0.3-3 µM). IMS 2186 (10 µM) decreases migration of THP-1 macrophages in wound healing and chamber assays. Subcutaneous administration of IMS 2186 (20 µg/animal) inhibits VEGF-induced blood vessel formation in a MatrigelTM plug assay in mice. It reduces ocular leakage, as well as cellular proliferation and infiltration in a rat model of laser-induced choroidal neovascularization when administered intravitreally at a dose of 100 µg/eye.
1.Falkenstein, I.A., Cheng, L., Wong-Staal, F., et al.Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186Curr. Eye Res.33(7)599-609(2008)
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *